-+ 0.00%
-+ 0.00%
-+ 0.00%

Sinco Pharma FY26 H1 profit attributable to owners drops 18.03% to RMB 19.91 million; revenue falls 13.7% to RMB 1.03 billion

PUBT·08/28/2026 08:47:30
Listen to the news
Sinco Pharma FY26 H1 profit attributable to owners drops 18.03% to RMB 19.91 million; revenue falls 13.7% to RMB 1.03 billion
  • Sinco Pharmaceuticals posted a 13.7% revenue drop to RMB 1.03 billion for the six months ended June 30, 2026.
  • Net profit attributable to owners fell 18.4% to RMB 19.91 million; basic and diluted EPS slid to RMB 0.0098.
  • Gross profit declined to RMB 124.09 million; gross margin widened 1.1 percentage points to 12%.
  • Selling and distribution expenses climbed to RMB 37.37 million; finance costs eased to RMB 13.77 million.
  • Medical aesthetics update: Girl Needle Type S filing accepted in January 2026; on-site inspection completed in March; supplementary information requested in April.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinco Pharmaceuticals Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304339), on August 28, 2026, and is solely responsible for the information contained therein.